Mersana Therapeutics, Inc.
MRSN
$29.05
$0.461.59%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 260.24% | 10.97% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 260.24% | 10.97% | |||
| Cost of Revenue | -24.89% | -11.58% | |||
| Gross Profit | 91.09% | 15.56% | |||
| SG&A Expenses | -15.00% | -16.92% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -21.78% | -13.32% | |||
| Operating Income | 63.67% | 16.05% | |||
| Income Before Tax | 68.95% | -0.72% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 68.95% | -0.72% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 68.95% | -0.72% | |||
| EBIT | 63.67% | 16.05% | |||
| EBITDA | 63.56% | 16.14% | |||
| EPS Basic | 68.98% | -0.55% | |||
| Normalized Basic EPS | 63.92% | 15.75% | |||
| EPS Diluted | 68.98% | -0.55% | |||
| Normalized Diluted EPS | 63.92% | 15.75% | |||
| Average Basic Shares Outstanding | 0.12% | 0.16% | |||
| Average Diluted Shares Outstanding | 0.12% | 0.16% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||